Skip to main content
Predictors of willingness to participate in HIV vaccine trials among African Americans
Journal of AIDS & Clinical Research
  • Mindy Ma, Nova Southeastern University
  • Toni A. Young, Community Education Group
  • Marcus Durham, Centers for Disease Control and Prevention
  • Jeffrey L. Kibler, Nova Southeastern University
  • Zaneta Gaul, Centers for Disease Control and Prevention
  • Sherri Pals, Centers for Disease Control and Prevention
  • Madeline Y. Sutton, Centers for Disease Control and Prevention
Document Type
Publication Date
African Americans in the United States (U.S.) are disproportionately affected by HIV. Developing an HIV vaccine is an important part of the HIV prevention and treatment toolkit and may help contribute to ending the HIV epidemic. To date, HIV vaccine trials have not engaged representative numbers of African Americans. We evaluated the willingness of African Americans to participate in HIV vaccine trials and identified correlates of willingness to participate (WTP) by surveying African Americans at low- and high-risk of HIV infection in a multi-site, cross-sectional study. We enrolled 1,452 participants; 59% heterosexual women; 21% heterosexual men; 20% men who have sex with men (MSM). Over half of participants (58%) expressed some level of WTP in HIV vaccine trials. Multivariable analyses revealed several variables were positively related to WTP: HIV risk behavior, knowing someone with HIV/AIDS, social support for trial participation, high perception of risk, perceived protection if in a trial, altruism, and greater tolerance for the ambiguous nature of trials (p<0.01). Emphasis on contextual factors related to personal HIV experiences, including knowledge of someone with HIV, and community support for research, may provide effective strategies for engaging African Americans in future HIV vaccine trials.
Citation Information
Ma M, Toni Young A, Durham M, Kibler JL, Gaul Z, et al. (2014) Predictors of Willingness of Participate in HIV Vaccine Trials among African Americans. J AIDS Clin Res 5: 361 doi: 10.4172/2155-6113.1000361